|Bid||1.58 x 800|
|Ask||1.65 x 2200|
|Day's Range||1.55 - 1.61|
|52 Week Range||1.34 - 2.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.58|
The Chesterbrook, Pennsylvania-based company said it had a loss of 13 cents per share. The biopharmaceutical company posted revenue of $2.5 million in the period. The company's shares closed at $1.49. ...
–Oliceridine NDA remains on track for a November 2, 2018 FDA decision–. –First license agreements for ex-US development and commercialization of oliceridine add potential revenue streams–. –Early pipeline ...
Trevena (NASDAQ: TRVN) is expecting an FDA decision on its pain drug oliceridine on November 2. Furthermore, the FDA has informed the company that it intends to convene an advisory committee meeting to discuss the oliceridine filing (likely in September), which could be a catalyst for shares if positive. Wall Street analysts continue to believe Olinvo will likely be approved by the FDA based on the draft guidelines and two positive pivotal Phase 3 APOLLO studies and ATHENA safety study.
LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on TRVN sign up now at www.wallstequities.com/registration. On Monday, July 09, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green.
Trevena, Inc. (TRVN) announced today the successful completion of its first-time-in-human Phase 1 study of TRV250, a biased delta receptor agonist that the Company is developing for the treatment of acute migraine. Preclinical data suggested that the novel selective signaling mechanism of TRV250 might avoid the seizure liability that has limited development of therapeutics targeting the delta receptor. Data from this healthy volunteer study showed safety, tolerability, and pharmacokinetics supporting the advancement of TRV250 to Phase 2 proof of concept evaluation in patients.
The Company has appointed Linda Wase, M.D. as Vice President of Medical Affairs, Michael Catalano as Vice President of Marketing, and Bob Yoder as Vice President of Sales & Commercial Operations. Linda Wase, M.D., has worked with Trevena since 2017, first as a consultant guiding Medical Affairs strategy and, since March 2018, as Vice President of Medical Affairs.
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want a free Stock Review on TGTX sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: TG Therapeutics Inc. (NASDAQ: TGTX), Trevena Inc. (NASDAQ: TRVN), United Therapeutics Corp. (NASDAQ: UTHR), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA).
Trevena (NASDAQ:TRVN) and Array Biopharma (NASDAQ:ARRY) investors could be celebrating soon enough, should these two drug makers achieve that triumphant FDA approval at the close of a winding biotech road. Between Trevena's opioid asset oliceridine, designed as an intravenous treatment of severe acute pain, and Array's BRAF-mutant melanoma combination therapy candidate encorafenib + binimetinib getting close to final FDA verdicts, two bulls at Cowen are out shedding light on the opportunity ahead. By Cowen's bet, these drug makers are steaming ahead to stamps of FDA approval.
Investors seeking to increase their exposure to growth should consider companies such as Trevena and Redfin. Analysts are generally optimistic about the future of these stocks, based on how muchRead More...
CHESTERBROOK, Pa., May 30, 2018-- Trevena, Inc. today announced that it will be presenting at the Jefferies Global Healthcare Conference on Wednesday, June 6 th, 2018, at 3:30 p.m. EDT in New York, NY.. ...
LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want access to our free research report on Trevena,Inc. (NASDAQ: TRVN), all you need to do is sign up now by clicking thefollowing link www.active-investors.com/registration-sg/?symbol=TRVN as the Company’s latest news hit the wire. OnMay 22, 2018, the Company, which is a biopharmaceutical organization developinginnovative therapies based on breakthrough science to benefit patients and healthcareproviders confronting serious medical conditions, announced that it showcasedtwo presentations at the American Society of Colon and Rectal Surgeons 2018Annual Scientific Meeting. Active-Investors.com is currently working on the researchreport for Albireo Pharma, Inc. (NASDAQ: ALBO), which also belongs to the Healthcaresector as the Company Trevena.
Trevena, Inc. (TRVN) today announced two presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting, held in Nashville, Tennessee, May 19-23. The first poster highlighted efficacy, safety and tolerability data from 115 colorectal patients from the ATHENA Phase 3 multicenter, open label safety study of Trevena's investigational product oliceridine. In the ATHENA study, oliceridine was administered to 768 patients with moderate-to-severe acute pain caused by medical conditions or surgery.
“Mark is a highly experienced pharmaceutical executive, with comprehensive experience developing therapeutics, shepherding them through the approval process, and leading post approval activities,” said Maxine Gowen, Ph.D., Chief Executive Officer. The Company also announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of May 21, 2018, the grant of inducement stock options to purchase 200,000 shares of the Company's common stock to Dr. Demitrack.
The licensing deal for rights to the Chester County's company opioid pain medicine with a new mechanism of action includes a $2.5 million upfront payment.
The Chesterbrook, Pennsylvania-based company said it had a loss of 14 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
The deal involves Trevena experimental pain medicine Olinvo, which it is developing as a safer alternative to traditional opioids. The FDA is reviewing a new drug application Trevena filed last year to market the drug in the United States.
The former GlaxoSmithKline executive has led the company, which is working on a new type of pain medicine, for the past decade. Her successor will be promoted from within the company.